OBJECTIVES: The COVID-19 pandemic threatened global HIV Test and Treat Efforts.
BACKGROUND: The East African Community (EAC) has experienced a significant increase in volume and complexity of clinical research driven by the epidemics of emerging and re-emerging infectious diseases such as HIV, Ebola, COVID-19, and
Cholera remains a significant public health burden in many countries in sub-Saharan Africa, though the exact mechanisms of bacterial emergence and spread remain largely undefined.
Hepatitis C virus (HCV) infection is associated with unfavorable multidrug- and rifampicin-resistant (MDR/RR) tuberculosis (TB) outcomes.
BACKGROUND: Despite its Sahelian context, Niger is one of the sub-Saharan countries reporting the highest number of malaria cases.
BACKGROUND: WHO recommends fractional dose vaccination to address yellow fever vaccine shortages during outbreaks.
BACKGROUND: Advanced HIV patients face high mortality, often from invasive bacterial infections (IBI), while rising antimicrobial resistance (AMR) threatens treatment.
BACKGROUND: Lassa fever is an emerging zoonotic disease endemic to west Africa.
BACKGROUND: Seasonal Malaria Chemoprevention (SMC) has been implemented in Moissala Health District, southern Chad, since 2013 using the standard regimen of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ).
In Niger, malaria remains a major public health issue and cause of economic loss, but its impact on young adults remains poorly documented. Although this population is central to the country's development, it is rarely studied.
